These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 15554754)

  • 21. Successful use of maintenance rTMS for 8 months in a patient with antipsychotic-refractory auditory hallucinations.
    Thirthalli J; Bharadwaj B; Kulkarni S; Gangadhar BN; Kharawala S; Andrade C
    Schizophr Res; 2008 Mar; 100(1-3):351-2. PubMed ID: 18252271
    [No Abstract]   [Full Text] [Related]  

  • 22. Cognitive improvement in response to antipsychotic drugs: neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
    Heinrichs RW
    Arch Gen Psychiatry; 2007 Jun; 64(6):631-2. PubMed ID: 17548745
    [No Abstract]   [Full Text] [Related]  

  • 23. Challenge to atypical antipsychotic drug effect on cognition.
    Carpenter WT; Conley RR
    Am J Psychiatry; 2007 Dec; 164(12):1910-1; author reply 1911-2. PubMed ID: 18056250
    [No Abstract]   [Full Text] [Related]  

  • 24. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis.
    Keefe RS; Silva SG; Perkins DO; Lieberman JA
    Schizophr Bull; 1999; 25(2):201-22. PubMed ID: 10416727
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cognitive effects of conventional and atypical antipsychotics in schizophrenia.
    Sharma T
    Br J Psychiatry Suppl; 1999; (38):44-51. PubMed ID: 10884899
    [No Abstract]   [Full Text] [Related]  

  • 26. [Schizophrenia and cognition: long-standing and current issues].
    Azorin JM; Da Fonseca D; Fakra E
    Encephale; 2011 Dec; 37 Suppl 2():S93-4. PubMed ID: 22212848
    [No Abstract]   [Full Text] [Related]  

  • 27. Neurocognitive functioning in schizophrenia: a trial of risperidone versus haloperidol.
    Addington J; Addington D
    Can J Psychiatry; 1997 Nov; 42(9):983. PubMed ID: 9429073
    [No Abstract]   [Full Text] [Related]  

  • 28. Effects of tapering of long-term benzodiazepines on cognitive function in patients with schizophrenia receiving a second-generation antipsychotic.
    Kitajima R; Miyamoto S; Tenjin T; Ojima K; Ogino S; Miyake N; Fujiwara K; Funamoto Y; Arai J; Tsukahara S; Ito Y; Tadokoro M; Anai K; Kaneda Y; Yamaguchi N
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Mar; 36(2):300-6. PubMed ID: 22122880
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Could repetitive transcranial magnetic stimulation improve neurocognition in early-onset schizophrenia spectrum disorders?
    Croarkin PE; Daskalakis ZJ
    J Am Acad Child Adolesc Psychiatry; 2012 Sep; 51(9):949-51. PubMed ID: 22917209
    [No Abstract]   [Full Text] [Related]  

  • 30. The effects of clozapine on cognitive functioning in schizophrenia.
    McGurk SR
    J Clin Psychiatry; 1999; 60 Suppl 12():24-9. PubMed ID: 10372607
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Symptom domains of schizophrenia: the role of atypical antipsychotic agents.
    Burton S
    J Psychopharmacol; 2006 Nov; 20(6 Suppl):6-19. PubMed ID: 17046984
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Typical and atypical antipsychotics: Is there a difference in their influence on neurocognition?].
    Faber G; van Gool AR; Smid HG; Wiersma D; van den Bosch RJ
    Tijdschr Psychiatr; 2011; 53(2):107-17. PubMed ID: 21319067
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Executive function in schizophrenia: what impact do antipsychotics have?
    O'Grada C; Dinan T
    Hum Psychopharmacol; 2007 Aug; 22(6):397-406. PubMed ID: 17579928
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential cognitive performances between schizophrenic responders and non-responders to antipsychotics: correlation with course of the illness, psychopathology, attitude to the treatment and antipsychotics doses.
    de Bartolomeis A; Balletta R; Giordano S; Buonaguro EF; Latte G; Iasevoli F
    Psychiatry Res; 2013 Dec; 210(2):387-95. PubMed ID: 23910239
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment.
    Harvey PD; Keefe RS
    Am J Psychiatry; 2001 Feb; 158(2):176-84. PubMed ID: 11156796
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of subjective cognitive and emotional effects of antipsychotic drugs. Effect by defect?
    Moritz S; Andreou C; Klingberg S; Thoering T; Peters MJ
    Neuropharmacology; 2013 Sep; 72():179-86. PubMed ID: 23643756
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Negative symptoms: which antipsychotics?].
    Maurel M; Belzeaux R; Adida M; Azorin JM
    Encephale; 2015 Dec; 41(6 Suppl 1):6S32-5. PubMed ID: 26776390
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cognitive neuroscience and schizophrenia: translational research in need of a translator.
    Cohen JD; Insel TR
    Biol Psychiatry; 2008 Jul; 64(1):2-3. PubMed ID: 18549873
    [No Abstract]   [Full Text] [Related]  

  • 39. Optimisation of long-term treatment in schizophrenia: treating the true spectrum of symptoms.
    Kasper S
    Eur Neuropsychopharmacol; 2006 Sep; 16 Suppl 3():S135-41. PubMed ID: 16872809
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Conceptualizing schizophrenia through attenuated symptoms in the population.
    Carpenter WT
    Am J Psychiatry; 2010 Sep; 167(9):1013-6. PubMed ID: 20826849
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.